Ceva is committed to swine vaccines with its Research and Development sites located in different continents worldwide investing substantial resources in innovation and production.

A number of firms (COGLA, Phylaxia Vet. Bio. Co) and researchers in the history of the Ceva Group have made their name by their veterinary research work, notably in the biological field.

For example, renowned scientists such as Aladar AUJEZSKY or Adorjan BARTHA have worked for Hungarian firm Phylaxia Vet. Bio. Co (today Ceva PHYLAXIA).

This scientific excellence has always been an integral part of the Group’s culture, developing adapted responses to the main infectious diseases affecting swine rearing today:

  • Classical swine fever: COGLAPEST® is an attenuated live vaccine with a coloured indicator allowing monitoring of vaccine efficacy.
  • Pleuropneumonia in pigs (Actinobacillus pleuropneumoniae): COGLAPIX® The only vaccine is based on bacterial toxoids, providing the best protection against all the serotypes of APP and minimal post-vaccination reactions at one and the same time.
  • Enzootic pneumonia (Mycoplasma hyopneumoniae): HYOGEN® The inactivated vaccine is based on the use of the unique proprietary adjuvant ImuvantTM, stimulating broadly the immune system. Single injection provides early and long lasting protection.
  • Aujeszky's disease: AUPHYL® Plus: new vaccine with specific adjuvant against Aujeszky's disease allowing eradication at farm  << coming soon >>


From one country to another, product lines are adapted to local demand and regulatory requirements. For further information, please take a look at the Ceva Santé Animale site for your country. Warning: the information provided on the products depends on national registrations. Access to technical information is restricted to authorised persons.

Back to top